Physician profile
Doris Ramirez Nessetti
NPI 1245409655
$4,960.27
in general payments reported to CMS, 2019-2025
44 companies · $851 in 2025
The $851 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $366 · 2021: $1,182 · 2022: $1,038 · 2023: $629 · 2024: $647 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,126.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $869.18 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $475.43 | 2020-2025 | |
| Lilly USA, LLC | $422.23 | 2020-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $389.01 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.73 | 2020-2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $299.33 | 2020-2024 | Rexulti |
| Indivior INC. | $233.02 | 2019-2025 | Sublocade |
| Astellas Pharma US INC | $184.73 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $173.57 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $140.28 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $134.79 | 2020-2021 | |
| Tempus Ai, INC | $131.78 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $105.54 | 2025 | Airsupra |
| Hologic Sales and Service, LLC | $104.02 | 2022-2024 | Aptima, Thinprep 2000 Processor |
| Takeda Pharmaceuticals U.S.A., INC. | $101.94 | 2021-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $85.01 | 2021-2023 | |
| Biogen, INC. | $82.64 | 2020-2021 | |
| Neuronetics, INC. | $59.06 | 2020-2023 | Neurostar Tms Therapy System |
| Shield Therapeutics INC | $45.40 | 2024-2025 | |
| Abbott Laboratories | $38.35 | 2019-2024 | Proclaim |
| Allergan, INC. | $37.75 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $34.75 | 2019 | |
| Organon LLC | $34.71 | 2021-2022 | |
| Exact Sciences Corporation | $32.83 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $32.69 | 2023-2025 | Myfembree |
| Nevro Corp. | $32.53 | 2023-2024 | Senza |
| Merck Sharp & Dohme LLC | $30.37 | 2020-2022 | |
| Antares Pharma, INC. | $29.65 | 2019-2023 | Xyosted, Nocdurna, Tlando |
| Organogenesis INC. | $25.87 | 2021 | |
| Currax Pharmaceuticals LLC | $25.06 | 2022 | |
| Therapeuticsmd, INC. | $23.86 | 2019 | |
| Philips North America LLC | $21.42 | 2025 | Diagnostic Ecg Service |
| Ethicon US, LLC | $19.17 | 2021 | |
| Livanova USA, INC. | $19.14 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.87 | 2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.98 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $16.71 | 2024 | Voquezna |
| Ascend Therapeutics US, LLC | $16.50 | 2019 | |
| Myovant Sciences INC. | $16.40 | 2022 | |
| Halozyme INC | $15.03 | 2023 | |
| Phadia US INC. | $14.13 | 2022 | |
| Fidia Pharma USA INC. | $13.30 | 2023 | Triluron, Hymovis |
| Agile Therapeutics, INC. | $11.87 | 2021 | |
| Minerva Surgical, INC | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Ramirez Nessetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.